Profound Medical (PROF) and Its Peers Head to Head Review

Profound Medical (NASDAQ:PROF) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Profound Medical to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Valuation and Earnings

This table compares Profound Medical and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profound Medical	$16.10 million	-$42.57 million	-7.31
Profound Medical Competitors	$1.89 billion	$138.79 million	11.30

Profound Medical’s competitors have higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Profound Medical and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
Profound Medical Competitors	-278.16%	-150.10%	-21.89%

Analyst Recommendations

This is a summary of current ratings and target prices for Profound Medical and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1	0	1	1	2.67
Profound Medical Competitors	4264	10506	18254	825	2.46

Profound Medical currently has a consensus price target of $11.50, indicating a potential upside of 60.61%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 16.49%. Given Profound Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Profound Medical is more favorable than its competitors.

Volatility & Risk

Profound Medical has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Profound Medical’s competitors have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.

Summary

Profound Medical competitors beat Profound Medical on 7 of the 13 factors compared.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.